Back to top

Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis

Celldex Therapeutics (($CLDX)) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is conducting a Phase 2 st...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Celldex Therapeutics, Inc. (CLDX)